Hemophilia, once a life-threatening condition marked by uncontrolled bleeding and limited treatment options, has seen remarkable advances in recent decades. Early treatments relied on frequent infusions of clotting factors, which offered temporary relief but came with high costs, burdensome schedules, and risks like viral infections. Today, thanks to groundbreaking research in genetics, we are entering a new era of precision medicine. Gene therapies and long-acting clotting factors are transforming the standard of care—offering many patients the potential for fewer treatments, fewer bleeds, and dramatically improved quality of life. In some clinical trials, gene therapy has led to sustained increases in clotting factor levels, effectively reducing or even eliminating the need for ongoing infusions. These life-changing advances were made possible by decades of genetic research—and there's still more to be discovered. By contributing your anonymized genetic data to 46forALL, you can play a vital role in accelerating the next generation of hemophilia breakthroughs. Your data will help researchers identify new genetic patterns, understand treatment response variability, and explore pathways to long-term cures. Together, we can unlock insights that not only improve lives for people with hemophilia, but also advance our understanding of other rare genetic disorders. Every dataset brings us closer to a future where no one is defined by their diagnosis.